Hermann Einsele

Hermann Christof Einsele (born 1958) is a German hematologist and oncologist and professor at the Julius Maximilians University of Würzburg. Provided by Wikipedia
Showing 1 - 8 results of 8 for search 'Hermann Einsele', query time: 0.15s Refine Results
  1. 1
    Rationale and design of the multicenter, national, randomized, open labeled phase III trial: allogeneic stem cell transplantation as a potential curative treatment for patients with relapsed or progressed multiple myeloma (AlloRelapseMM Study)

    Rationale and design of the multicenter, national, randomized, open labeled phase III trial: allogeneic stem cell transplantation as a potential curative treatment for patients wit... by Annemarie Glöckner, Stefan Schönland, Hermann Einsele, Nicolaus Kröger

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer

    Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer by Michael Hudecek, Achim Wöckel, Jörg Wischhusen, Tanja Stüber, Razieh Monjezi, Lars Wallstabe, Johanna Kühnemundt, Sarah Louise Nietzer, Gudrun Dandekar, Hermann Einsele

    Published 2020-05-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategies

    Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategies by Max Topp, Michael Hudecek, Hermann Einsele, Imad Maatouk, Leo Rasche, Johannes Duell, Anna Fleischer, Sophia Kurth, Patrick-Pascal Strunz, Julia Mersi, Carmen Sanges

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Therapeutic advances in the targeting of ROR1 in hematological cancers

    Therapeutic advances in the targeting of ROR1 in hematological cancers by Adrian-Bogdan Tigu, Raluca Munteanu, Cristian Moldovan, Drula Rares, David Kegyes, Radu Tomai, Vlad Moisoiu, Gabriel Ghiaur, Ciprian Tomuleasa, Hermann Einsele, Diana Gulei, Carlo M. Croce

    Published 2024-11-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?

    Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies? by Hermann Einsele, Anca Colita, Dana Tomescu, Sabina Iluta, Sergiu Pasca, Delia Dima, Ciprian Tomuleasa, Catalin Vlad, Catalin Constantinescu, Tiberiu Tat, Patric Teodorescu, Ecaterina Scarlatescu, Alina Tanase, Olafur Eysteinn Sigurjonsson

    Published 2020-05-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition

    Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition by Johannes M. Waldschmidt, Johannes M. Waldschmidt, Lukas Haug, Lukas Haug, Christine Riedhammer, Christine Riedhammer, Christoph K. W. Deinzer, Marcus Zimmermann, Marcus Zimmermann, Anke Heidemeier, Anke Heidemeier, Peter Raab, Peter Raab, Maximilian Rudert, Maximilian Rudert, Anne Hendricks, Anne Hendricks, Johan F. Lock, Johan F. Lock, Viktoria Buck, Viktoria Buck, Andreas Rosenwald, Andreas Rosenwald, Hermann Einsele, Hermann Einsele, Peter Reichardt, Volker Kunzmann, Volker Kunzmann, Armin Wiegering, Armin Wiegering, Daniel Pink, Daniel Pink, K. Martin Kortüm, K. Martin Kortüm

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML

    Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML by Julia M. Unglaub, Richard F. Schlenk, Jan Moritz Middeke, Stefan W. Krause, Sabrina Kraus, Hermann Einsele, Michael Kramer, Sven Zukunft, Joseph Kauer, Simon Renders, Elena Katelari, Christoph Schliemann, Caroline Pabst, Thomas Luft, Peter Dreger, Christoph Röllig, Martin Bornhäuser, Carsten Müller-Tidow, Tim Sauer

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, randomized, phase II clinical trial (ELIAS-Trial)

    Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnose... by Theo Leitner, Evgenii Shumilov, Christina Schwitlick, Raphael Koch, Franziska Hamm, Marion Högner, Florian Bassermann, Katja Weisel, Hermann Einsele, Martin Kortüm, Leo Rasche, Martin Görner, Kai Wegehenkel, Stefan Knop, Jan Krönke, Axel Nogai, Inke R. König, Maren Vens, Kay Horn, Nikolas von Bubnoff, Cyrus Khandanpour

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: